Akcea Therapeutics (NASDAQ:AKCA) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a report issued on Saturday, December 30th.
A number of other research analysts have also recently weighed in on the company. Zacks Investment Research cut Akcea Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Stifel Nicolaus reaffirmed a “buy” rating and set a $20.00 price objective (up previously from $19.00) on shares of Akcea Therapeutics in a research note on Tuesday, November 7th. Finally, Cowen reaffirmed a “buy” rating on shares of Akcea Therapeutics in a research note on Tuesday, October 31st. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. Akcea Therapeutics presently has a consensus rating of “Buy” and an average target price of $22.75.
Akcea Therapeutics (NASDAQ:AKCA) opened at $17.00 on Friday. Akcea Therapeutics has a 52-week low of $8.10 and a 52-week high of $31.23.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc acquired a new stake in shares of Akcea Therapeutics during the third quarter valued at $111,000. Strs Ohio acquired a new stake in Akcea Therapeutics in the 3rd quarter worth about $118,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Akcea Therapeutics in the 3rd quarter worth about $180,000. Nationwide Fund Advisors acquired a new stake in Akcea Therapeutics in the 3rd quarter worth about $209,000. Finally, Wells Fargo & Company MN acquired a new stake in Akcea Therapeutics in the 3rd quarter worth about $222,000. 26.04% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Akcea Therapeutics (NASDAQ:AKCA) Lowered to “Hold” at BidaskClub” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/01/14/bidaskclub-lowers-akcea-therapeutics-akca-to-hold.html.
About Akcea Therapeutics
Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).
Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.